Yarrow Bioscience (YARW) Net Margin (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly Net Margin came in at 8.0% in Q2 2025, down 244.0% YoY from 5.56% in Q2 2024, and down 100.0% on a QoQ basis from 4.0% in Q1 2025.
Yarrow Bioscience (YARW) Net Margin (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 9 years of Net Margin data on file, last reported at 8.0% in Q2 2025.
- Quarterly Net Margin fell 244.0% year-over-year to 8.0% in Q2 2025, while the trailing twelve-month figure through Mar 2026 was 3.41% (up 107.0% YoY) and the FY2025 annual result came in at 44.39%, up 4979.0% from the prior year.
- Net Margin retreated to 8.0% in Q2 2025, from 4.0% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 7507.87% in Q1 2022 to a low of 7531.03% in Q4 2022.
- A 5-year average of 863.44% and a median of 47.37% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin surged 1171395 bps — and 2023, when it tumbled 751787 bps.
- Tracing YARW's Net Margin over 5 years: stood at 1171.43% in 2021, then tumbled by 543 bps to 7531.03% in 2022, then surged by 99 bps to 47.37% in 2023, then surged by 80 bps to 9.64% in 2024, then climbed by 17 bps to 8.0% in 2025.
- The last three Net Margin figures came in at 8.0% (Q2 2025), 4.0% (Q1 2025), and 9.64% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 12.09% |
| 10 | Yarrow Bioscience | 31.22 Mn | 8.30 Mn | - | -3,007.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -108.00% |
| Jun 30, 2025 | -8.00% |
| Mar 31, 2025 | -4.00% |
| Dec 31, 2024 | -9.64% |
| Jun 30, 2024 | -5.56% |
| Mar 31, 2024 | -8.00% |
| Dec 31, 2023 | -47.37% |
| Sep 30, 2023 | -450.00% |
| Jun 30, 2023 | -20.00% |
| Mar 31, 2023 | -10.00% |
| Dec 31, 2022 | -7,531.03% |
| Sep 30, 2022 | -122.16% |
| Jun 30, 2022 | -191.27% |
| Mar 31, 2022 | 7,507.87% |
| Dec 31, 2021 | -1,171.43% |
| Sep 30, 2021 | -5,269.92% |
| Jun 30, 2021 | -3,131.86% |
| Mar 31, 2021 | -4,206.09% |
| Dec 31, 2020 | -540.85% |
| Sep 30, 2020 | -756.01% |